Stay updated on Atrasentan in IgA Nephropathy Clinical Trial
Sign up to get notified when there's something new on the Atrasentan in IgA Nephropathy Clinical Trial page.

Latest updates to the Atrasentan in IgA Nephropathy Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check33 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2; no visible changes to the study details or layout are observed.SummaryDifference0.0%

- Check40 days agoChange DetectedRevision 3.4.1 replaces 3.4.0, indicating a minor maintenance update with no substantive changes to the study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check54 days agoChange DetectedAdded: Show glossary, Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0; Removed: Last Update Submitted that met QC Criteria, No FEAR Act data, Revision: v3.3.4.SummaryDifference0.1%

- Check61 days agoChange Detected- Revision updated from v3.3.3 to v3.3.4 in the page header. This is a metadata change and does not modify the study details, eligibility criteria, or locations.SummaryDifference0.0%

- Check90 days agoChange DetectedThe study Locations list was updated to add new sites across the U.S., Argentina, Australia, Italy, China, India, Spain, and other regions, and several previously listed locations were removed.SummaryDifference2%

Stay in the know with updates to Atrasentan in IgA Nephropathy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Atrasentan in IgA Nephropathy Clinical Trial page.